http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Lee, Hyo-Jeong,Jung, Deok-Beom,Sohn, Eun Jung,Kim, Hanna Hyun,Park, Moon Nyeo,Lew, Jae-Hwan,Lee, Seok Geun,Kim, Bonglee,Kim, Sung-Hoon Hindawi Publishing Corporation 2012 Evidence-based Complementary and Alternative Medic Vol.2012 No.-
<P>Although cryptotanshinone (CT) was known to exert antitumor activity in several cancers, its molecular mechanism under hypoxia still remains unclear. Here, the roles of AEG-1 and HIF-1<I><I>α</I></I> in CT-induced antitumor activity were investigated in hypoxic PC-3 cells. CT exerted cytotoxicity against prostate cancer cells and suppressed HIF-1<I><I>α</I></I> accumulation and AEG-1 expression in hypoxic PC-3 cells. Also, AEG-1 was overexpressed in prostate cancer cells. Interestingly, HIF-1<I><I>α</I></I> siRNA transfection enhanced the cleavages of caspase-9,3, and PAPR and decreased expression of Bcl-2 and AEG1 induced by CT in hypoxic PC-3 cells. Of note, DMOG enhanced the stability of AEG-1 and HIF-1<I><I>α</I></I> during hypoxia. Additionally, CT significantly reduced cellular level of VEGF in PC-3 cells and disturbed tube formation of HUVECs. Consistently, ChIP assay revealed that CT inhibited the binding of HIF-1<I><I>α</I></I> to VEGF promoter. Furthermore, CT at 10 mg/kg suppressed the growth of PC-3 cells in BALB/c athymic nude mice by 46.4% compared to untreated control. Consistently, immunohistochemistry revealed decreased expression of Ki-67, CD34, VEGF, carbonic anhydrase IX, and AEG-1 indices in CT-treated group compared to untreated control. Overall, our findings suggest that CT exerts antitumor activity via inhibition of HIF-1<I><I>α</I></I>, AEG1, and VEGF as a potent chemotherapeutic agent.</P>
신기능 저하 환자의 조영제 신독성 예방을 위한 N-acetylcysteine 복용과 수액요법의 비교
서정숙 ( Jeong Sook Seo ),전혜정 ( Hae Jung Jun ),구호석 ( Ho Seok Koo ),이원동 ( Won Dong Lee ),강선우 ( Sun Woo Kang ),김영훈 ( Yeong Hoon Kim ),김양욱 ( Yang Wook Kim ),이정녀 ( Jeong Nyeo Lee ),박성한 ( Sung Han Park ),이준식 대한내과학회 2007 대한내과학회지 Vol.73 No.4
목적: 조영제로 인한 신부전(contrast induced nephropathy, CIN)은 신기능 저하 환자에게 있어 급성신부전의 중요한 원인 중 하나이다. 이러한 CIN의 예방 방법으로서 N-acetylcysteine (NAC)와 수액 공급 병합요법이 효과적으로 알려져 있다. 그러나 단독 수액요법 또한 예방효과가 있다고 보고되고 있다. 이에 저자들은 신기능저하 환자에게 있어 단독 경구 NAC 투여가 단독 수액요법과 비교하여 CIN의 예방에 유사한 효과가 있는지, 혈관 확장제인 nitric oxide의 요중 배설에 차이가 있는지를 비교함으로써 향후 충분한 수액요법을 하기 힘든 경우, 경구 NAC 투여만으로 CIN의 예방이 가능한가를 알아보기 위해 본 연구를 시행하였다. 방법: 비이온성, 저삼투성 조영제를 이용한 방사선학적 검사(복부 컴퓨터 단층 촬영 또는 관상동맥 조영술)가 필요한 27명의 신기능 저하 환자를 대상으로 하였다. CIN의 정의는 급성 신부전이 발생할 특별한 원인 없이 조영제 사용 전에 비교하여 사용 후 48시간 내에 혈청크레아티닌이 0.5 mg/dL 이상 증가하는 것으로 정의하였다. 이 환자들 중 11명은 NAC 600 mg을 하루 두 번 복용시켰고, 16명은 0.45% saline을 1 mL/kg/Hr의 비율로 조영제를 투여하기 전 12시간 동안과 조영제 사용 후 12시간 동안 투여하였다. 환자들을 대상으로 조영제를 투여하기 전과 투여 후의 혈청 크레아티닌, FENa, 크레아티닌 청소율을 측정하였다. 그리고 NAC 투여한 5명과 수액 군의 10명을 대상으로 조영제 사용 전과 사용 48시간 후의 요중 nitrite를 측정하였다. 결과: 사용한 조영제의 평균 양(100.9±54.8 vs 114.7±38 mL; p=0.43) 및 기본 혈청 크레아티닌의 수치는 양 군에서 차이가 없었다(2.31±1.59 vs 2.18±1.4 mg/dL; p=0.98). CIN의 발생 빈도는 NAC군과 수액요법군에서 18.2%와 12.5%로 두 군 간의 유의할만한 차이가 없었다(p=1.0). 또한 조영제 사용 전 혈청 크레아티닌이 CIN발생에 가장 중요한 위험 요소였다. 뇨 nitrite/크레아티닌 비(μmol/mg)는 NAC군에서는 투여 전, 후 각각 1.26±0.57, 1.43±0.64였고, 수액요법군에서는 0.80±0.40, 1.18±0.60로 두 군 간의 유의한 차이는 없었다. 조영제 노출 후 수액용법군에 비해 NAC군에서 FENa는 증가하였다(p=0.04). 결론: 단독 경구 NAC 투여 역시 CIN의 예방에 효과적이었다. 이에 따라 수액투여가 금기시 되는 신기능 저하 환자에 있어 CIN의 예방에 NAC 단독요법이 효과적일 것으로 사료된다. Background: Contrast induced nephropathy (CIN) is an important cause of acute renal failure in patients with renal dysfunction. We investigated whether oral NAC alone was sufficient to prevent CIN to the same extent as hydration in patients with renal dysfunction, and whether these treatments resulted in diffierences in the urinary excretion of nitric oxide, a vasodilator. Methods: A total of 27 patients with renal dysfunction, who underwent radiographic examination with nonionic and low osmolar contrast, were randomly assigned to receive either NAC (600 mg orally twice daily; N=11) or 0.45% saline hydration (1 mL/kg/Hr; N=16) 12 hours prior to and 12 hours after the contrast procedure. We measured serum creatinine (sCr), fractional excretion of sodium (FENa), creatinine clearance (CCr), and urinary nitrite before and after contrast administration. Results: The mean volume of contrast used was similar in the two groups (100.9±54.8 mL vs 114.7±38 mL; p=0.43), as was baseline sCr in the two groups (2.31±1.59 mg/dL vs 2.18±1.41 mg/dL; p=0.98). Treatment did not significantly affect the incidence of CIN, with 18.2% and 12.5% in the NAC group and hydration group, respectively (p=1.0). The urinary nitrite/creatinine ratio (μmol/mg) was 1.26±0.57 and 1.43±0.64 at baseline and 48 hours after contrast exposure in the NAC group, respectively, and 0.80±0.40 and 1.18±0.60 in the hydration group, respectively, which were not significantly different. FENa increased significantly after contrast exposure in the NAC group compared with hydration group (p=0.04) Conclusions: NAC alone may prevent CIN. When bolus hydration is contraindicated in patients with renal dysfunction, administration of NAC alone may be sufficient.(Korean J Med 73:361-367, 2007)
Shin, Jeong Hwan,Jung, Hee Jung,Lee, Ja Young,Kim, Hye Ran,Lee, Jeong Nyeo,Chang, Chulhun Ludgerus Mary Ann Liebert 2008 Microbial Drug Resistance Vol.14 No.3
<P>The aims of this study were to investigate the prevalence of qnrA, qnrB, and qnrS determinants and their molecular characteristics in ciprofloxacin-resistant isolates of Escherichia coli and Klebsiella pneumoniae from urinary tract infections (UTI) in Korea. A total of 202 nonduplicated clinical isolates of ciprofloxacin-resistant E. coli (n = 143) and K. pneumoniae (n = 59) were collected between July 2005 and August 2006. The qnr determinant screening was carried out by PCR amplification of qnrA, qnrB, and qnrS, and all positive results were confirmed by direct sequencing of the PCR products. For qnr-positive strains and their conjugants, antimicrobial susceptibility tests and pulsed-field gel electrophoresis (PFGE) were performed. The qnrB gene was detected in 41 of the 202 isolates. Among 33 of 59 (55.9%) K. pneumoniae isolates showing qnrB, 29 isolates contained the qnrB4 gene, 3 isolates had the qnrB2 gene, and 1 isolate had the qnrB6 gene. All 8 (5.6%) of the qnrB-positive isolates among the 143 E. coli strains possessed the qnrB4 gene. The minimum inhibitory concentrations (MICs) of ciprofloxacin for the transconjugants were 0.03-2 mug/ml, representing an increase of 4- to 256-fold relative to the recipient, E. coli J53Az(r). Resistances to various other antimicrobial agents also were transferred with the plasmid. The PFGE analysis revealed indistinguishable or closely related patterns in several strains and highly diverse patterns in general. QnrB variants, especially the qnrB4 subtype, are highly prevalent in ciprofloxacin-resistant E. coli and K. pneumoniae from UTI in Korea. The emergence of plasmid-mediated quinolone resistance may contribute by several means to the rapid increase in bacterial resistance to these drugs.</P>
Risk Factor and Mortality in Patients with Pulmonary Embolism Combined with Infectious Disease
( Gi Dong Lee ),( Sunmi Ju ),( Ju-young Kim ),( Tae Hoon Kim ),( Jung-wan Yoo ),( Seung Jun Lee ),( Yu Ji Cho ),( Yi Yeong Jeong ),( Kyung Nyeo Jeon ),( Jong Deog Lee ),( Ho Cheol Kim ) 대한결핵 및 호흡기학회 2020 Tuberculosis and Respiratory Diseases Vol.83 No.2
Background: Infectious conditions may increase the risk of venous thromboembolism. The purpose of this study was to evaluate the risk factor for combined infectious disease and its influence on mortality in patients with pulmonary embolism (PE). Methods: Patients with PE diagnosed based on spiral computed tomography findings of the chest were retrospectively analyzed. They were classified into two groups: patients who developed PE in the setting of infectious disease or those with PE without infection based on review of their medical charts. Results: Of 258 patients with PE, 67 (25.9%) were considered as having PE combined with infectious disease. The sites of infections were the respiratory tract in 52 patients (77.6%), genitourinary tract in three patients (4.5%), and hepatobiliary tract in three patients (4.5%). Underlying lung disease (odds ratio [OR], 3.69; 95% confidence interval [CI], 1.926-7.081; p<0.001), bed-ridden state (OR, 2.84; 95% CI, 1.390-5.811; p=0.004), and malignant disease (OR, 1.867; 95% CI, 1.017-3.425; p=0.044) were associated with combined infectious disease in patients with PE. In-hospital mortality was higher in patients with PE combined with infectious disease than in those with PE without infection (24.6% vs. 11.0%, p=0.006). In the multivariate analysis, combined infectious disease (OR, 4.189; 95% CI, 1.692-10.372; p=0.002) were associated with non-survivors in patients with PE. Conclusion: A substantial portion of patients with PE has concomitant infectious disease and it may contribute a mortality in patients with PE.
( An Na Lee ),( Se Il Go ),( Won Sup Lee ),( Un Seok Lee ),( Moon Jin Kim ),( Myung Hee Kang ),( Gyeong Won Lee ),( Hoon Gu Kim ),( Jung Hun Kang ),( Kyung Nyeo Jeon ),( Jae Min Cho ),( Jeong Hee Le ) 대한내과학회 2013 대한내과학회 추계학술대회 Vol.2013 No.1
The standard regimen has not been determined yet for taxane- and anthracycline-refractory triple-negative breast cancer (TNBC). Capecitabine was approved by Food and Drug Administration (FDA) for the treatment of the advanced breast cancer and has efficacy in the treatment of advanced breast cancer refractory to anthracycline and taxane. Irinotecan has synergism with 5-fluorouracil and shows efficacy in the advanced breast cancer. Here, we report a patient with TNBC who relapsed with wide spread bone and lung metastasis shortly after adjuvant anthracycline followed by taxane chemotherapy. She achieved metabolic complete response (CR) after irinotecan and capecitabine combination chemotherapy and showed 10-month of progression-free survival and 22-month. She relapsed with and died of brain metastasis without any definite signs of progression of the lung and bone lesions that she had had before irinotecan and capecitabine combination chemotherapy. To validate this favorable result, larger clinical trials are warranted in metastatic or relapsed TNBC patients.